Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 1 de 1
Add filters

Document Type
Year range
Viruses ; 14(10)2022 09 27.
Article in English | MEDLINE | ID: covidwho-2066543


Curcumin, the bioactive compound of the spice Curcuma longa, has already been reported as a potential COVID-19 adjuvant treatment due to its immunomodulatory and anti-inflammatory properties. In this study, SARS-CoV-2 was challenged with curcumin; moreover, curcumin was also coupled with laser light at 445 nm in a photodynamic therapy approach. Curcumin at a concentration of 10 µM, delivered to the virus prior to inoculation on cell culture, inhibited SARS-CoV-2 replication (reduction >99%) in Vero E6 cells, possibly due to disruption of the virion structure, as observed using the RNase protection assay. However, curcumin was not effective as a prophylactic treatment on already-infected Vero E6 cells. Notably, when curcumin was employed as a photosensitizer and blue laser light at 445 nm was delivered to a mix of curcumin/virus prior to the inoculation on the cells, virus inactivation was observed (>99%) using doses of curcumin that were not antiviral by themselves. Photodynamic therapy employing crude curcumin can be suggested as an antiviral option against SARS-CoV-2 infection.

COVID-19 Drug Treatment , Curcumin , Chlorocebus aethiops , Animals , Humans , SARS-CoV-2 , Photosensitizing Agents/pharmacology , Photosensitizing Agents/chemistry , Curcumin/pharmacology , Antiviral Agents/pharmacology , Antiviral Agents/therapeutic use , Vero Cells , Anti-Inflammatory Agents/pharmacology , Ribonucleases/pharmacology , Virus Replication